Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM

Olmos, Vanessa Pachón; Gallo, M.J. Ramos; Rebollo, Maite Antonio; Ortega, Dolores Ballesteros; Docampo, Lara Iglesias; Romera-Villegas, Antonio; Díaz, Enrique; Martín, A. Muñoz

doi:10.1016/s0025-7753(15)30012-9

Cited by 8 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most cancer outpatients do not require routine prevention (2B). 21,23,27,28 It may be suitable for preventing for the following types of particularly high-risk VTE conditions: multiple myeloma with thalidomide or lenalidomide regimens, 23,27,28 high Khorana scores, 23,37 some with a prior history of VTE. 23 The duration of the prophylaxis and the indications for discontinuation were unknown; low-molecular-weight heparin (LMWH) was recommended (2B).…”

Section: Venous Thromboembolism Prevention and Treatment In Patients With Cancer And Status Of Noac In Catmentioning

confidence: 99%

“…34 The prophylaxis was 12 to 2 hours before operation or 6 to 12 hours after the operation, usually lasting for 7 to 10 days (1A). 28,33 The duration of prevention of extensive abdominal and pelvic surgery is 4 weeks (1B). 19,28,31 The use of LMWH, fondaparinux, and UFH depends on the patient's characteristics.…”

Section: Venous Thromboembolism Prevention and Treatment In Patients With Cancer And Status Of Noac In Catmentioning

confidence: 99%

See 1 more Smart Citation

Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants

Zhang

et al. 2019

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Cancer-associated thrombosis (CAT) studies have increased in recent years and the quality of guidelines to guide the clinical practice of CAT prevention and treatment becomes crucial. The therapy status of new oral anticoagulants (NOACs) has been established in some thrombotic diseases, but the evidence for CAT remains unconvincing. The aim of this research is to evaluate the quality of CAT guidelines and discuss the role of NOAC in CAT. A search of articles was performed using PubMed/Medline, Chinese National Knowledge Infrastructure, and other authoritative websites. Search terms included guideline or guidance, consensuses, cancer, and thrombosis. Appraisal of Guidelines for Research & Evaluation II (AGREE II) tool was used to evaluate the qualities of the guidelines. A total of 19 guidelines were screened out and evaluated, of which 8 were recommended, 5 were recommended after revision, and 6 were not recommended. For prevention and treatment of CAT, low-molecular-weight heparin is the most recommended, followed by vitamin K antagonist, unfractionated heparin, fondaparinux, and aspirin. New oral anticoagulant is optional in some cases of CAT treatment. Based on AGREE II assessment tool, the quality of CAT guidelines is inconsistent. Attention should be drawn to the quality of CAT guidelines during clinical practice. The role of NOAC in the treatment of CAT is gradually established but requires more supporting evidence from future clinical trials.

show abstract

Section: Venous Thromboembolism Prevention and Treatment In Patients With Cancer And Status Of Noac In Catmentioning

confidence: 99%

Section: Venous Thromboembolism Prevention and Treatment In Patients With Cancer And Status Of Noac In Catmentioning

confidence: 99%

Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants

Zhang

et al. 2019

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…►Table 2 summarizes useful criteria to guide decisions. 43,44,[57][58][59] In fact, the use of LMWH in this setting relies on general clinical trials of CAT. In general, anticoagulation for a minimum period of 3 months is recommended, even if the CVC is removed earlier.…”

Section: Suggestionsmentioning

confidence: 99%

“…Although the quality of the evidence is low, international guidelines suggest that in cancer patients with incidental splanchnic VT, anticoagulant treatment should be considered in a case-by-case basis, taking into account clinical data suggestive of chronic thrombus, such as collateral circulation or portal cavernomatosis. 42,58 No recommendation about the need of an upper gastrointestinal endoscopy to look for esophageal varices that could be treated before starting anticoagulant therapy is made. There are no specific recommendations according to the splanchnic vein involved either.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines—A Multidisciplinary (SEMI–SEOM–SETH) Expert Consensus

Pachón

Trujillo‐Santos

Domènech

et al. 2018

TH Open

View full text Add to dashboard Cite

Despite the growing interest and improved knowledge about venous thromboembolism in cancer patients in the last years, there are still many unsolved issues. Due to the limitations of the available literature, evidence-based clinical practice guidelines are not able to give solid recommendations for challenging scenarios often present in the setting of cancer-associated thrombosis (CAT). A multidisciplinary expert panel from three scientific societies—Spanish Society of Internal Medicine (SEMI), Spanish Society of Medical Oncology (SEOM), and Spanish Society Thrombosis and Haemostasis (SETH)—agreed on 12 controversial questions regarding prevention and management of CAT, which were thoroughly reviewed to provide further guidance. The suggestions presented herein may facilitate clinical decisions in specific complex circumstances, until these can be made leaning on reliable scientific evidence.

show abstract

FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

et al. 2017

View full text Add to dashboard Cite

show abstract

Manejo de la enfermedad tromboembólica venosa en pacientes oncológicos: guías de práctica clínica española. Consenso SEACV-SEOM

Cited by 8 publications

References 0 publications

Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants

Quality Appraisal of Guidelines on Cancer-Associated Thrombosis Using AGREE II Instrument and Analysis of Current Status of New Oral Anticoagulants

Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines—A Multidisciplinary (SEMI–SEOM–SETH) Expert Consensus

FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

Contact Info

Product

Resources

About